Fennec Pharmaceuticals In... (FENC)
NASDAQ: FENC
· Real-Time Price · USD
8.39
-0.14 (-1.64%)
At close: Aug 15, 2025, 3:59 PM
8.36
-0.36%
After-hours: Aug 15, 2025, 04:10 PM EDT
Fennec Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 8.75M | 7.92M | 6.97M | 7.26M | 25.38M | 9.73M | 6.51M | 3.33M | 1.68M | 1.53M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 373K | 669K | 1.36M | 608K | 550K | 685K | 331K | 148K | 95K | 86K | 60.4K | 7.93K | 7.09K | n/a | n/a | n/a | n/a |
Gross Profit | 8.38M | 7.26M | 5.62M | 6.65M | 24.83M | 9.05M | 6.18M | 3.18M | 1.58M | 1.45M | -60.4K | -7.93K | -7.09K | n/a | n/a | n/a | n/a |
Operating Income | -808K | -934K | -5.2M | -5.04M | 13.74M | -1.82M | -1.02M | -4.67M | -5.27M | -6.13M | -7.9M | -5.01M | -3.55M | -4.21M | -4.17M | -3.92M | -4.92M |
Interest Income | 235.29K | 374K | 516K | 570K | 197K | 115K | 102K | 116.52K | 109K | 153K | 24K | 8.92K | 9K | 13K | 12.91K | 12K | 16K |
Pretax Income | -1.17M | -1.62M | -5.74M | -5.55M | 12.84M | -2.68M | -1.87M | -5.44M | -6.05M | -6.86M | -8.09M | -5.07M | -3.7M | -4.41M | -4.16M | -4M | -4.77M |
Net Income | -1.17M | -1.99M | -5.74M | -5.55M | 12.84M | -2.68M | -1.87M | -5.44M | -6.05M | -7.79M | -8.09M | -5.06M | -3.79M | -4.43M | -4.18M | -4M | -4.73M |
Selling & General & Admin | 9.09M | 8.14M | 10.72M | 11.54M | 11.08M | 10.84M | 7.19M | 7.83M | 6.85M | 7.47M | 7.05M | 3.88M | 2.11M | 3.68M | 2.93M | 3.12M | 2.51M |
Research & Development | 94K | 50K | 97K | 157K | 3K | 32K | 12K | 8K | 4K | 117K | 846K | 1.13M | 1.44M | 523K | 1.24M | 800K | 2.42M |
Other Expenses | n/a | n/a | n/a | n/a | n/a | -72K | n/a | n/a | n/a | 86K | n/a | n/a | n/a | 9K | -1K | n/a | -8K |
Operating Expenses | 9.19M | 8.19M | 10.82M | 11.69M | 11.08M | 10.87M | 7.2M | 7.84M | 6.85M | 7.67M | 7.9M | 5.01M | 3.55M | 4.21M | 4.17M | 3.92M | 4.92M |
Interest Expense | 603.17K | 966K | 1.02M | 1.07M | 1.03M | 915K | 856K | 909.86K | 798K | 815.23K | 119K | 56.51K | 58K | 62K | 54.63K | 9K | 4K |
Selling & Marketing Expenses | 2.95M | 3.94M | 4.6M | 4.67M | 5.21M | 3.87M | 3.38M | 2.34M | 2.53M | 2.79M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 9.56M | 8.86M | 12.18M | 12.3M | 11.63M | 11.55M | 7.53M | 7.99M | 6.95M | 7.67M | 7.9M | 5.01M | 3.55M | 4.21M | 4.17M | 3.92M | 4.92M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 935K | 71K | -14K | 92K | 62K | 46K | -3K | -16K |
Shares Outstanding (Basic) | 27.58M | 27.46M | 27.37M | 27.3M | 27.05M | 26.83M | 26.46M | 26.46M | 26.56M | 26.36M | 26.09M | 26.05M | 26.02M | 26.01M | 26.01M | 26M | 26M |
Shares Outstanding (Diluted) | 27.58M | 27.46M | 27.37M | 27.3M | 31.09M | 26.83M | 26.46M | 26.46M | 26.56M | 26.36M | 26.11M | 26.05M | 26.02M | 26.01M | 26.01M | 26M | 26M |
EPS (Basic) | -0.04 | -0.06 | -0.21 | -0.2 | 0.47 | -0.1 | -0.07 | -0.21 | -0.29 | -0.3 | -0.31 | -0.19 | -0.15 | -0.17 | -0.16 | -0.15 | -0.18 |
EPS (Diluted) | -0.04 | -0.06 | -0.21 | -0.2 | 0.41 | -0.1 | -0.07 | -0.21 | -0.29 | -0.3 | -0.31 | -0.19 | -0.15 | -0.17 | -0.16 | -0.15 | -0.18 |
EBITDA | -547K | -628K | -4.68M | -4.48M | 14.59M | -1.7M | -939K | -4.62M | -5.18M | -6.11M | -7.9M | -5.01M | -3.63M | -4.37M | -4.13M | -3.99M | -4.73M |
EBIT | -558K | -610K | -4.73M | -4.49M | 13.87M | -1.77M | -1.01M | -4.62M | -5.25M | -6.11M | -7.97M | -5.01M | -3.64M | -4.37M | -4.13M | -3.99M | -4.73M |
Depreciation & Amortization | 26K | 26K | 25K | 26K | 723K | 70K | 72K | -52K | 52K | 169K | 60.4K | 7.93K | 7K | -8K | 8K | 3.92M | 4.92M |